FindMyKOL
Clinical trialNCT01501123CompletedInterventional

Pre-hospital Agitation and Sedation Trial: A Randomized Controlled Trial of Haloperidol Versus Midazolam for the Sedation of the Agitated Patient

SponsorCatholic Health EastEnrollment10Agitation
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

PREHOSPITAL AGITATION AND SEDATION TRIAL (PHAST) * The goal of the PHAST is to demine whether haloperidol is superior to midazolam for the sedation of agitated patients in the prehospital environment * The primary outcome is the time to a Richmond Agitation and Sedation Scale (RASS) ≤1 o The RASS is a well validated standardized score to measure a patient's agitation * The secondary outcomes are * Time until RASS returns to 0 or 1 if RASS \<0 * Need for additional sedation * Adverse effects (need for intubation, arrhythmia) * Mercy EMS will be the only EMS agency in the Commonwealth of Pennsylvania carrying haloperidol * Identification of potential study patients will be per state protocols * Exclusion Criteria for the study * Age \<18 * Pregnant * Allergic to study medication * Transport to hospital other than Mercy Fitzgerald Hospital * Unable to reach medical command prior to giving medication * When a paramedic identifies a possible study candidate, the paramedic will consult medical command to see if the patient is appropriate for the study * If the medical command agrees the patient is appropriate for the study, patients will be randomized to * Odd days: Haloperidol 5mg IM (age \<65) or haloperidol 2.5 mg IM (age ≥65) * Even days: Midazolam 0.05 mg IM to maximum of 5mg IM (age \<65) or maximum of 2.5mg (age ≥65) * The RASS will be documented by the prehospital providers every 5 minutes until arrival at the hospital * Once the patient arrives at the ED, the RASS will be documented in PICIS® by the emergency department nurse at the time of triage and at a minimum of hourly until the RASS =0 or 1 for 2 consecutive hours * Questions may be directed to Dr. Isenberg at disenberg@mercyhealth.org or at (267) 205-6453 Richmond Agitation Sedation Scale RASS RASS Description * 4 Combative, violent, danger to staff * 3 Pulls or removes tube(s) or catheters; aggressive * 2 Frequent non-purposeful movement * 1 Anxious, apprehensive, but not aggressive 0 Alert and calm * 1 Awakens to voice (eye opening/contact) \>10 sec * 2 Light sedation, briefly awakens to voice (eye opening/contact) \<10 sec * 3 Moderate sedation, movement or eye opening. No eye contact * 4 Deep sedation, no response to voice, but movement or eye opening to physical stimulation * 5 Unarousable, no response to voice or physical stimulation

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Mercy Catholic Medical Center

    Darby, Pennsylvania, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
30 Nov 2011
Primary completion
31 Oct 2015
Completion
31 Dec 2015
Last update posted
24 Jul 2019
Registered enrollment
10
Registry id
NCT01501123

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 4 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.